4CPS-264 Population pharmacokinetic model of etanercept in rheumatic disease: prognostic factors and dose recommendations

BACKGROUND: Etanercept is an approved monoclonal antibody for the treatment of rheumatic disease (RD). Individual clinical response to etanercept can be influenced by their pharmacokinetics (PK) and immunogenicity, so therapeutic drug monitoring (TDM) can guide these biologic treatments. PURPOSE: De...

全面介紹

Na minha lista:
書目詳細資料
發表在:Eur J Hosp Pharm
Main Authors: Sanchez-Hernandez, JG, Pérez-Blanco, JS, Beunza-Sola, M, Rebollo-Diaz, N, Saez-Fernandez, EM, Laso-Lucas, E, Rodriguez-Cajaraville, L, Calvo, MV
格式: Artigo
語言:Inglês
出版: BMJ Group 2018
主題:
Section 4: Clinical pharmacy services
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535412/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.354
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍